Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 208

1.

NMR quantification of lactate production and efflux and glutamate fractional enrichment in living human prostate biopsies cultured with [1,6-13 C2 ]glucose.

Bancroft Brown J, Sriram R, VanCriekinge M, Delos Santos R, Sun J, Delos Santos J, Tabatabai ZL, Shinohara K, Nguyen H, Peehl DM, Kurhanewicz J.

Magn Reson Med. 2019 Aug;82(2):566-576. doi: 10.1002/mrm.27739. Epub 2019 Mar 28.

PMID:
30924180
2.

A spliced form of CD44 expresses the unique glycan that is recognized by the prostate cancer specific antibody F77.

Chen X, Nagai Y, Zhu Z, Ruan H, Peehl DM, Greene MI, Zhang H.

Oncotarget. 2017 Dec 16;9(3):3631-3640. doi: 10.18632/oncotarget.23341. eCollection 2018 Jan 9.

3.

Bioorthogonal Labeling of Human Prostate Cancer Tissue Slice Cultures for Glycoproteomics.

Spiciarich DR, Nolley R, Maund SL, Purcell SC, Herschel J, Iavarone AT, Peehl DM, Bertozzi CR.

Angew Chem Int Ed Engl. 2017 Jul 24;56(31):8992-8997. doi: 10.1002/anie.201701424. Epub 2017 Jun 26.

4.

The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry.

Zhao H, Ning S, Nolley R, Scicinski J, Oronsky B, Knox SJ, Peehl DM.

Clin Epigenetics. 2017 Jan 19;9:4. doi: 10.1186/s13148-017-0312-z. eCollection 2017.

5.

Cabozantinib inhibits tumor growth and metastasis of a patient-derived xenograft model of papillary renal cell carcinoma with MET mutation.

Zhao H, Nolley R, Chan AMW, Rankin EB, Peehl DM.

Cancer Biol Ther. 2017 Nov 2;18(11):863-871. doi: 10.1080/15384047.2016.1219816. Epub 2016 Aug 11.

6.

Endoscopic detection of cancer with lensless radioluminescence imaging and machine vision.

Türkcan S, Naczynski DJ, Nolley R, Sasportas LS, Peehl DM, Pratx G.

Sci Rep. 2016 Aug 1;6:30737. doi: 10.1038/srep30737.

7.

Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer.

Saeed K, Rahkama V, Eldfors S, Bychkov D, Mpindi JP, Yadav B, Paavolainen L, Aittokallio T, Heckman C, Wennerberg K, Peehl DM, Horvath P, Mirtti T, Rannikko A, Kallioniemi O, Östling P, Af Hällström TM.

Eur Urol. 2017 Mar;71(3):319-327. doi: 10.1016/j.eururo.2016.04.019. Epub 2016 May 6.

8.

Spheroid culture of LuCaP 136 patient-derived xenograft enables versatile preclinical models of prostate cancer.

Valta MP, Zhao H, Saar M, Tuomela J, Nolley R, Linxweiler J, Sandholm J, Lehtimäki J, Härkönen P, Coleman I, Nelson PS, Corey E, Peehl DM.

Clin Exp Metastasis. 2016 Apr;33(4):325-37. doi: 10.1007/s10585-016-9781-2. Epub 2016 Feb 12.

PMID:
26873136
9.

A Protective Role for Androgen Receptor in Clear Cell Renal Cell Carcinoma Based on Mining TCGA Data.

Zhao H, Leppert JT, Peehl DM.

PLoS One. 2016 Jan 27;11(1):e0146505. doi: 10.1371/journal.pone.0146505. eCollection 2016.

10.

Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity.

Zhao H, Ning S, Scicinski J, Oronsky B, Knox SJ, Peehl DM.

Oncotarget. 2015 Dec 22;6(41):43172-81. doi: 10.18632/oncotarget.6526.

11.

Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study.

Reid T, Oronsky B, Scicinski J, Scribner CL, Knox SJ, Ning S, Peehl DM, Korn R, Stirn M, Carter CA, Oronsky A, Taylor MJ, Fitch WL, Cabrales P, Kim MM, Burris HA Rd, Lao CD, Abrouk NED, Fanger GR, Infante JR.

Lancet Oncol. 2015 Sep;16(9):1133-1142. doi: 10.1016/S1470-2045(15)00089-3. Epub 2015 Aug 19.

PMID:
26296952
12.

Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001.

Ning S, Sekar TV, Scicinski J, Oronsky B, Peehl DM, Knox SJ, Paulmurugan R.

Oncotarget. 2015 Aug 28;6(25):21547-56.

13.

Metabolic response of prostate cancer to nicotinamide phophoribosyltransferase inhibition in a hyperpolarized MR/PET compatible bioreactor.

Keshari KR, Wilson DM, Van Criekinge M, Sriram R, Koelsch BL, Wang ZJ, VanBrocklin HF, Peehl DM, O'Brien T, Sampath D, Carano RA, Kurhanewicz J.

Prostate. 2015 Oct;75(14):1601-9. doi: 10.1002/pros.23036. Epub 2015 Jul 14.

14.

Elevated serum microRNA levels associate with absence of high-grade prostate cancer in a retrospective cohort.

Mihelich BL, Maranville JC, Nolley R, Peehl DM, Nonn L.

PLoS One. 2015 Apr 14;10(4):e0124245. doi: 10.1371/journal.pone.0124245. eCollection 2015.

15.

Hepcidin regulation in prostate and its disruption in prostate cancer.

Tesfay L, Clausen KA, Kim JW, Hegde P, Wang X, Miller LD, Deng Z, Blanchette N, Arvedson T, Miranti CK, Babitt JL, Lin HY, Peehl DM, Torti FM, Torti SV.

Cancer Res. 2015 Jun 1;75(11):2254-63. doi: 10.1158/0008-5472.CAN-14-2465. Epub 2015 Apr 9.

16.

Coordinate loss of MAP3K7 and CHD1 promotes aggressive prostate cancer.

Rodrigues LU, Rider L, Nieto C, Romero L, Karimpour-Fard A, Loda M, Lucia MS, Wu M, Shi L, Cimic A, Sirintrapun SJ, Nolley R, Pac C, Chen H, Peehl DM, Xu J, Liu W, Costello JC, Cramer SD.

Cancer Res. 2015 Mar 15;75(6):1021-34. doi: 10.1158/0008-5472.CAN-14-1596.

17.

A strategy for tissue self-organization that is robust to cellular heterogeneity and plasticity.

Cerchiari AE, Garbe JC, Jee NY, Todhunter ME, Broaders KE, Peehl DM, Desai TA, LaBarge MA, Thomson M, Gartner ZJ.

Proc Natl Acad Sci U S A. 2015 Feb 17;112(7):2287-92. doi: 10.1073/pnas.1410776112. Epub 2015 Jan 29.

18.

Spheroid culture of LuCaP 147 as an authentic preclinical model of prostate cancer subtype with SPOP mutation and hypermutator phenotype.

Saar M, Zhao H, Nolley R, Young SR, Coleman I, Nelson PS, Vessella RL, Peehl DM.

Cancer Lett. 2014 Sep 1;351(2):272-80. doi: 10.1016/j.canlet.2014.06.014. Epub 2014 Jul 3.

19.

Nuclear KLLN expression associates with improved relapse-free survival for prostate carcinoma.

Wang Y, Roma A, Nolley R, Abdul-Karim F, Peehl DM, Eng C.

Endocr Relat Cancer. 2014 Aug;21(4):579-86. doi: 10.1530/ERC-14-0148.

PMID:
24972837
20.

Determination of carbohydrate structure recognized by prostate-specific F77 monoclonal antibody through expression analysis of glycosyltransferase genes.

Nonaka M, Fukuda MN, Gao C, Li Z, Zhang H, Greene MI, Peehl DM, Feizi T, Fukuda M.

J Biol Chem. 2014 Jun 6;289(23):16478-86. doi: 10.1074/jbc.M114.559047. Epub 2014 Apr 21.

21.

Carbohydrate sequence of the prostate cancer-associated antigen F77 assigned by a mucin O-glycome designer array.

Gao C, Liu Y, Zhang H, Zhang Y, Fukuda MN, Palma AS, Kozak RP, Childs RA, Nonaka M, Li Z, Siegel DL, Hanfland P, Peehl DM, Chai W, Greene MI, Feizi T.

J Biol Chem. 2014 Jun 6;289(23):16462-77. doi: 10.1074/jbc.M114.558932. Epub 2014 Apr 21.

22.

Development of a realistic in vivo bone metastasis model of human renal cell carcinoma.

Valta MP, Zhao H, Ingels A, Thong AE, Nolley R, Saar M, Peehl DM.

Clin Exp Metastasis. 2014 Jun;31(5):573-84. doi: 10.1007/s10585-014-9651-8. Epub 2014 Apr 9.

23.

Phosphorylcholine-coated semiconducting polymer nanoparticles as rapid and efficient labeling agents for in vivo cell tracking.

Pu K, Shuhendler AJ, Valta MP, Cui L, Saar M, Peehl DM, Rao J.

Adv Healthc Mater. 2014 Aug;3(8):1292-8. doi: 10.1002/adhm.201300534. Epub 2014 Mar 25.

24.

Optimization and comprehensive characterization of a faithful tissue culture model of the benign and malignant human prostate.

Maund SL, Nolley R, Peehl DM.

Lab Invest. 2014 Feb;94(2):208-21. doi: 10.1038/labinvest.2013.141. Epub 2013 Dec 2.

25.

Imaging the glycosylation state of cell surface glycoproteins by two-photon fluorescence lifetime imaging microscopy.

Belardi B, de la Zerda A, Spiciarich DR, Maund SL, Peehl DM, Bertozzi CR.

Angew Chem Int Ed Engl. 2013 Dec 23;52(52):14045-9. doi: 10.1002/anie.201307512. Epub 2013 Nov 20. No abstract available.

26.

Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts.

Ingels A, Zhao H, Thong AE, Saar M, Valta MP, Nolley R, Santos J, Peehl DM.

Int J Cancer. 2014 May 15;134(10):2322-9. doi: 10.1002/ijc.28579. Epub 2013 Nov 18.

27.

Radioprotection and cell cycle arrest of intestinal epithelial cells by darinaparsin, a tumor radiosensitizer.

Tian J, Doi H, Saar M, Santos J, Li X, Peehl DM, Knox SJ.

Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):1179-85. doi: 10.1016/j.ijrobp.2013.08.051. Epub 2013 Oct 24.

PMID:
24210080
28.

A tissue graft model of DNA damage response in the normal and malignant human prostate.

Af Hällström TM, Zhao H, Tian J, Rantanen V, Reese SW, Nolley R, Laiho M, Peehl DM.

J Urol. 2014 Mar;191(3):842-9. doi: 10.1016/j.juro.2013.09.007. Epub 2013 Sep 11.

29.

Patient-derived tissue slice grafts accurately depict response of high-risk primary prostate cancer to androgen deprivation therapy.

Zhao H, Thong A, Nolley R, Reese SW, Santos J, Ingels A, Peehl DM.

J Transl Med. 2013 Aug 28;11:199. doi: 10.1186/1479-5876-11-199.

30.

Tissue slice grafts of human renal cell carcinoma: an authentic preclinical model with high engraftment rate and metastatic potential.

Thong AE, Zhao H, Ingels A, Valta MP, Nolley R, Santos J, Young SR, Peehl DM.

Urol Oncol. 2014 Jan;32(1):43.e23-30. doi: 10.1016/j.urolonc.2013.05.008. Epub 2013 Aug 2.

31.

Establishment and serial passage of cell cultures derived from LuCaP xenografts.

Young SR, Saar M, Santos J, Nguyen HM, Vessella RL, Peehl DM.

Prostate. 2013 Sep;73(12):1251-62. doi: 10.1002/pros.22610. Epub 2013 Jun 6.

32.

Induced pluripotency of human prostatic epithelial cells.

Zhao H, Sun N, Young SR, Nolley R, Santos J, Wu JC, Peehl DM.

PLoS One. 2013 May 22;8(5):e64503. doi: 10.1371/journal.pone.0064503. Print 2013.

33.

Metabolic reprogramming and validation of hyperpolarized 13C lactate as a prostate cancer biomarker using a human prostate tissue slice culture bioreactor.

Keshari KR, Sriram R, Van Criekinge M, Wilson DM, Wang ZJ, Vigneron DB, Peehl DM, Kurhanewicz J.

Prostate. 2013 Aug;73(11):1171-81. doi: 10.1002/pros.22665. Epub 2013 Mar 26.

34.

Anti-Oligomannose Antibodies as Potential Serum Biomarkers of Aggressive Prostate Cancer.

Wang D, Dafik L, Nolley R, Huang W, Wolfinger RD, Wang LX, Peehl DM.

Drug Dev Res. 2013 Mar;74(2):65-80.

35.

Transcription factor KLLN inhibits tumor growth by AR suppression, induces apoptosis by TP53/TP73 stimulation in prostate carcinomas, and correlates with cellular differentiation.

Wang Y, Radhakrishnan D, He X, Peehl DM, Eng C.

J Clin Endocrinol Metab. 2013 Mar;98(3):E586-94. doi: 10.1210/jc.2012-3490. Epub 2013 Feb 5.

36.

Transcript levels of androgen receptor variant AR-V1 or AR-V7 do not predict recurrence in patients with prostate cancer at indeterminate risk for progression.

Zhao H, Coram MA, Nolley R, Reese SW, Young SR, Peehl DM.

J Urol. 2012 Dec;188(6):2158-64. doi: 10.1016/j.juro.2012.08.014. Epub 2012 Oct 22.

PMID:
23088973
37.

Darinaparsin: solid tumor hypoxic cytotoxin and radiosensitizer.

Tian J, Zhao H, Nolley R, Reese SW, Young SR, Li X, Peehl DM, Knox SJ.

Clin Cancer Res. 2012 Jun 15;18(12):3366-76. doi: 10.1158/1078-0432.CCR-11-3179. Epub 2012 Apr 25.

38.

Microfluidic integration for automated targeted proteomic assays.

Hughes AJ, Lin RK, Peehl DM, Herr AE.

Proc Natl Acad Sci U S A. 2012 Apr 17;109(16):5972-7. doi: 10.1073/pnas.1108617109. Epub 2012 Apr 2.

39.

Suppression of Tak1 promotes prostate tumorigenesis.

Wu M, Shi L, Cimic A, Romero L, Sui G, Lees CJ, Cline JM, Seals DF, Sirintrapun JS, McCoy TP, Liu W, Kim JW, Hawkins GA, Peehl DM, Xu J, Cramer SD.

Cancer Res. 2012 Jun 1;72(11):2833-43. doi: 10.1158/0008-5472.CAN-11-2724. Epub 2012 Mar 30.

40.

Integrated analysis reveals critical genomic regions in prostate tumor microenvironment associated with clinicopathologic phenotypes.

Ashida S, Orloff MS, Bebek G, Zhang L, Zheng P, Peehl DM, Eng C.

Clin Cancer Res. 2012 Mar 15;18(6):1578-87. doi: 10.1158/1078-0432.CCR-11-2535. Epub 2012 Jan 24.

41.

Stiffness mapping prostate biopsy samples using a tactile sensor.

Peng Q, Omata S, Peehl DM, Constantinou CE.

Conf Proc IEEE Eng Med Biol Soc. 2011;2011:8515-8. doi: 10.1109/IEMBS.2011.6092101.

PMID:
22256325
42.

Cell surface glycoproteomic analysis of prostate cancer-derived PC-3 cells.

Hubbard SC, Boyce M, McVaugh CT, Peehl DM, Bertozzi CR.

Bioorg Med Chem Lett. 2011 Sep 1;21(17):4945-50. doi: 10.1016/j.bmcl.2011.05.045. Epub 2011 May 18.

43.

DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer.

Kobayashi Y, Absher DM, Gulzar ZG, Young SR, McKenney JK, Peehl DM, Brooks JD, Myers RM, Sherlock G.

Genome Res. 2011 Jul;21(7):1017-27. doi: 10.1101/gr.119487.110. Epub 2011 Apr 26.

44.

The alternative splice variant of protein tyrosine kinase 6 negatively regulates growth and enhances PTK6-mediated inhibition of β-catenin.

Brauer PM, Zheng Y, Evans MD, Dominguez-Brauer C, Peehl DM, Tyner AL.

PLoS One. 2011 Mar 30;6(3):e14789. doi: 10.1371/journal.pone.0014789.

45.

Metalloporphyrin synergizes with ascorbic acid to inhibit cancer cell growth through fenton chemistry.

Tian J, Peehl DM, Knox SJ.

Cancer Biother Radiopharm. 2010 Aug;25(4):439-48. doi: 10.1089/cbr.2009.0756.

PMID:
20735206
46.

Anti-tumor and radiosensitization activities of the iron chelator HDp44mT are mediated by effects on intracellular redox status.

Tian J, Peehl DM, Zheng W, Knox SJ.

Cancer Lett. 2010 Dec 8;298(2):231-7. doi: 10.1016/j.canlet.2010.07.010. Epub 2010 Aug 1.

PMID:
20678860
47.

Serum Mac-2BP does not distinguish men with high grade, large volume prostate cancer from men with benign prostatic hyperplasia.

Peehl DM, Chen Z, Nolley R.

Prostate. 2011 Jan 1;71(1):26-31. doi: 10.1002/pros.21218.

PMID:
20583127
48.

Tissue slice grafts: an in vivo model of human prostate androgen signaling.

Zhao H, Nolley R, Chen Z, Peehl DM.

Am J Pathol. 2010 Jul;177(1):229-39. doi: 10.2353/ajpath.2010.090821. Epub 2010 May 14.

49.

Targeting monoamine oxidase A in advanced prostate cancer.

Flamand V, Zhao H, Peehl DM.

J Cancer Res Clin Oncol. 2010 Nov;136(11):1761-71. doi: 10.1007/s00432-010-0835-6. Epub 2010 Mar 4.

50.

Methods for metabolic evaluation of prostate cancer cells using proton and (13)C HR-MAS spectroscopy and [3-(13)C] pyruvate as a metabolic substrate.

Levin YS, Albers MJ, Butler TN, Spielman D, Peehl DM, Kurhanewicz J.

Magn Reson Med. 2009 Nov;62(5):1091-8. doi: 10.1002/mrm.22120.

Supplemental Content

Loading ...
Support Center